Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement

Yasunori Iida, Akihiro Yoshitake, Hideyuki Shimizu

研究成果: Article査読

抄録

Background: Postoperative fluid overload in cardiovascular surgery is associated with increased mortality and morbidity. Recently, tolvaptan (TLV), a selective vasopressin V2 antagonist, has been used for perioperative fluid management. This study aimed to validate the safety and effectiveness of TLV administration after total arch replacement (TAR) using selective cerebral perfusion. Methods: From August 2016 to December 2016, 11 patients who had undergone TAR for thoracic aortic aneurysm were included in this study. In addition to the conventional diuretics furosemide (20 mg) and spironolactone (25 mg), TLV (7.5 mg) was administered orally. Results: TLV increased urine output 1-3 days after administration. Body weight was gradually and steadily reduced until discharge. Neither renal nor liver dysfunction was recognized during the TLV administration. Conclusion: The concomitant use of TLV and conventional diuretics is safe and effective for fluid management after TAR using cardiopulmonary bypass, selective cerebral perfusion, and hypothermic circulatory arrest.

本文言語English
ページ(範囲)103-107
ページ数5
ジャーナルAnnals of Vascular Surgery
56
DOI
出版ステータスPublished - 2019 4

ASJC Scopus subject areas

  • 外科
  • 循環器および心血管医学

フィンガープリント

「Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル